JP2024535145A - 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用 - Google Patents

改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用 Download PDF

Info

Publication number
JP2024535145A
JP2024535145A JP2024513977A JP2024513977A JP2024535145A JP 2024535145 A JP2024535145 A JP 2024535145A JP 2024513977 A JP2024513977 A JP 2024513977A JP 2024513977 A JP2024513977 A JP 2024513977A JP 2024535145 A JP2024535145 A JP 2024535145A
Authority
JP
Japan
Prior art keywords
mva
mirblock
seq
rsv
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535145A5 (enExample
Inventor
ハウスマン・ユルゲン
カッラ・マルクス
シュヴェネカー・マルク
ハビャン・マティアス
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2024535145A publication Critical patent/JP2024535145A/ja
Publication of JP2024535145A5 publication Critical patent/JP2024535145A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024513977A 2021-09-03 2022-09-02 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用 Pending JP2024535145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21194940.9 2021-09-03
EP21194940 2021-09-03
PCT/EP2022/074510 WO2023031428A1 (en) 2021-09-03 2022-09-02 Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva)

Publications (2)

Publication Number Publication Date
JP2024535145A true JP2024535145A (ja) 2024-09-27
JP2024535145A5 JP2024535145A5 (enExample) 2025-08-12

Family

ID=77640525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513977A Pending JP2024535145A (ja) 2021-09-03 2022-09-02 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用

Country Status (10)

Country Link
US (1) US20240392257A1 (enExample)
EP (1) EP4396333A1 (enExample)
JP (1) JP2024535145A (enExample)
KR (1) KR20240051214A (enExample)
CN (1) CN118234850A (enExample)
AU (1) AU2022338199A1 (enExample)
CA (1) CA3230406A1 (enExample)
IL (1) IL311078A (enExample)
MX (1) MX2024002641A (enExample)
WO (1) WO2023031428A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024188801A1 (en) * 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
AU2024396470A1 (en) * 2023-12-08 2026-06-04 Bavarian Nordic A/S Downregulation of yield-reducing transgenes expressed by poxvirus
WO2025153852A1 (en) * 2024-01-17 2025-07-24 1. Revvity Gene Delivery Gmbh Production of viral vectors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151631A2 (en) * 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
US20100029003A1 (en) * 2004-12-23 2010-02-04 Whitehead Institute For Biomedical Research System and methods for identifying miRNA targets and for altering miRNA and target expression
JP2012519484A (ja) * 2009-03-06 2012-08-30 マウント・シナイ・スクール・オヴ・メディシン マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン
US20130280215A1 (en) * 2011-10-18 2013-10-24 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
JP2015524660A (ja) * 2012-08-01 2015-08-27 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
CN106636310A (zh) * 2015-10-30 2017-05-10 益善生物技术股份有限公司 前列腺癌相关microRNA检测试剂盒
CN106636315A (zh) * 2015-10-30 2017-05-10 益善生物技术股份有限公司 淋巴瘤相关microRNA检测试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
GB2469043B (en) * 2009-03-30 2011-02-23 Lotus Car A reheated gas turbine system having a fuel cell
MX380483B (es) 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029003A1 (en) * 2004-12-23 2010-02-04 Whitehead Institute For Biomedical Research System and methods for identifying miRNA targets and for altering miRNA and target expression
WO2008151631A2 (en) * 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
JP2012519484A (ja) * 2009-03-06 2012-08-30 マウント・シナイ・スクール・オヴ・メディシン マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン
US20130280215A1 (en) * 2011-10-18 2013-10-24 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
JP2015524660A (ja) * 2012-08-01 2015-08-27 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
CN106636310A (zh) * 2015-10-30 2017-05-10 益善生物技术股份有限公司 前列腺癌相关microRNA检测试剂盒
CN106636315A (zh) * 2015-10-30 2017-05-10 益善生物技术股份有限公司 淋巴瘤相关microRNA检测试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Identification of Tissue-Specific MicroRNAs from Mouse", CURRENT BIOLOGY, vol. 12, JPN7026002995, 30 April 2002 (2002-04-30), pages 735 - 739, ISSN: 0005905844 *

Also Published As

Publication number Publication date
AU2022338199A1 (en) 2024-03-14
CN118234850A (zh) 2024-06-21
CA3230406A1 (en) 2023-03-09
KR20240051214A (ko) 2024-04-19
EP4396333A1 (en) 2024-07-10
WO2023031428A1 (en) 2023-03-09
US20240392257A1 (en) 2024-11-28
MX2024002641A (es) 2024-05-10
IL311078A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
JP7551157B2 (ja) Ｈｉｖワクチン接種および免疫療法
US20240238406A1 (en) Hiv pre-immunization and immunotherapy
US20240392257A1 (en) Utilization of Micro-RNA for Downregulation of Cytotoxic Transgene Expression by Modified Vaccinia Virus Ankara (MVA)
US12343390B2 (en) Recombinant biologically contained filovirus vaccine
EP2631290A1 (en) Virus vector for prime/boost vaccines, which comprises vaccinia virus vector and sendai virus vector
CN110462029A (zh) 无预先免疫步骤的hiv免疫疗法
CN116348132A (zh) 基于合成的被修饰的痘苗安卡拉（smva）的冠状病毒疫苗
Burgers et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C
Zhu et al. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes
US20250304995A1 (en) Modified parapoxvirus having increased immunogenicity
US20240043870A1 (en) Modified parapoxvirus having increased immunogenicity
US20100034851A1 (en) AIDS Vaccine Based on Replicative Vaccinia Virus Vector
JP7034818B2 (ja) 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法
Pérez Ramírez et al. An MVA vector expressing HIV-1 envelope under the control of a potent vaccinia virus promoter as a promising strategy in HIV/AIDS vaccine design
WO2026104601A1 (en) Viral vectors for enhanced immune responses to multimeric protein particle displayed antigens
Hefferon Applications for Virus Vaccine Vectors in Infectious Disease Research
WO2024188801A1 (en) Use of quail cell lines for poxvirus production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260708